PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Leflunomide - Rheumatology indications
PAD Profile : Leflunomide - Rheumatology indications
Keywords :
RMOC, national shared Care, Vasculitis (off label), Rheumatoid Arthritis, Psoriatic Arthritis, SLE (off label), Systemic Lupus Erythematosus (off label) , axial spondyloarthropathy (off label)
Brand Names Include :
Arava
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Hydroxychloroquine sulfate
- Mycophenolate mofetil
- Azathioprine
- Ciclosporin
- Methotrexate
- Sulfasalazine
Other Indications
Additional Documents
Type
Document
Review Date
Shared Care
Shared Care
01 January 2025
Shared Care
Committee Recommendations
Date
Committee Name
Narrative
02 August 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications
03 May 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approve the RMOC national shared care protocol with ‘local adaptations.
The local adaptation is:
Specialist Responsibilities
- The initiating specialist will be expected to initiate and optimise treatment and prescribe the maintenance treatment for at least 12 weeks and until optimised.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs